ArticleOncology letters2018
Identification of genes that predict the biochemical recurrence of prostate cancer.
Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Assessment of biochemical recurrence of prostate cancer (Review).International journal of oncology · 2019Pooled it
- Downregulation of GNPNAT1 impaired proliferation and correlates with immune infiltration in lung adenocarcinoma.Discover oncology · 2026Article
- Prediction of biochemical prostate cancer recurrence from any Gleason score using robust tissue structure and clinically available information.Discover oncology · 2025Article
- Association between serum urea nitrogen levels and prostate-specific antigens (NHANES 2003-2010).Journal of health, population, and nutrition · 2024Article
- Predicting prostate cancer recurrence: Introducing PCRPS, an advanced online web server.Heliyon · 2024Article
- Prediction of prostate cancer biochemical recurrence by using discretization supports the critical contribution of the extra-cellular matrix genes.Scientific reports · 2023Article
- Identification and construction of a 13-gene risk model for prognosis prediction in hepatocellular carcinoma patients.Journal of clinical laboratory analysis · 2022Article
- Predicting biochemical-recurrence-free survival using a three-metabolic-gene risk score model in prostate cancer patients.BMC cancer · 2022Article
- Deep Learning-Based Multi-Omics Integration Robustly Predicts Relapse in Prostate Cancer.Frontiers in oncology · 2022Article
- PCSK9 Axis-Targeting Pseurotin A as a Novel Prostate Cancer Recurrence Suppressor Lead.ACS pharmacology & translational science · 2021Article
- A Novel Approach for the Discovery of Biomarkers of Radiotherapy Response in Breast Cancer.Journal of personalized medicine · 2021Article
- Upregulation of glucosamine-phosphate N-acetyltransferase 1 is a promising diagnostic and predictive indicator for poor survival in patients with lung adenocarcinoma.Oncology letters · 2021Article
- Article
- Limitations of Explainability for Established Prognostic Biomarkers of Prostate Cancer.Frontiers in genetics · 2021Article
- The Impact of Cand1 in Prostate Cancer.Cancers · 2020Article
- Differentially Expressed Genes Associated With Prognosis in Locally Advanced Lymph Node-Negative Prostate Cancer.Frontiers in genetics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer (PCa) is one of the most prevalent cancer types in men. Biochemical recurrence continues to occur in a large proportion of patients after radical prostatectomy. Thus, prognostic biomarkers are required to determine which treatment is suitable. In the present study, RNA-sequencing gene expression data from The Cancer Genome Atlas was used in order to develop a risk-score staging system based on the expression of eight genes. Cox multivariate regression was used to predict the outcome of patients with PCa. The biomedical recurrence-free survival of patients with low-risk scores was significantly longer compared with patients with high-risk scores (P=5×10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.